MedTrace Logo

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NCT05417321 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-01-03

No results posted yet for this study

Summary

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor
  • NSCLC

Interventions

DRUG

HB0036

Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).

Sponsors & Collaborators

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yang Yang, MD/PHD · Shanghai Huaota Biopharmaceutical Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-25
Primary Completion
2025-08-01
Completion
2025-08-01
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05417321 on ClinicalTrials.gov